Additionally, the observation that ERVE-4- and hERV47000-derived epitopes were able elicit a tumor-restricted CD8+ T-cell response were the basis for an ongoing phase 1 trial evaluating the safety and efficacy of the infusion of ERVE-4 TCR-transduced CD8+/CD34+-enriched T cells (NCT03354390) [304]. Here, CD34 is linked to neoplasm.